Sonid Past Earnings Performance
Past criteria checks 0/6
Sonid's earnings have been declining at an average annual rate of -67.5%, while the Chemicals industry saw earnings growing at 7.9% annually. Revenues have been growing at an average rate of 8.2% per year.
Key information
-67.5%
Earnings growth rate
-55.1%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | 8.2% |
| Return on equity | -32.7% |
| Net Margin | -54.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Sonid Inc. (KOSDAQ:060230) Might Not Be As Mispriced As It Looks After Plunging 37%
Jul 29
Sonid Inc. (KOSDAQ:060230) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Jun 10Sonid Inc.'s (KOSDAQ:060230) 26% Share Price Plunge Could Signal Some Risk
Apr 26Here's Why exax (KOSDAQ:060230) Can Manage Its Debt Responsibly
May 04Is There More Growth In Store For exax's (KOSDAQ:060230) Returns On Capital?
Feb 12
Is exax (KOSDAQ:060230) Using Too Much Debt?
Jan 07Does exax's (KOSDAQ:060230) Share Price Gain of 27% Match Its Business Performance?
Dec 03Revenue & Expenses Breakdown
How Sonid makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 62,224 | -34,068 | 27,574 | 2,179 |
| 31 Mar 24 | 56,918 | -39,441 | 24,287 | 1,883 |
| 31 Dec 23 | 49,519 | -40,190 | 20,694 | 1,663 |
| 30 Sep 23 | 13,111 | -34,583 | 10,703 | 375 |
| 30 Jun 23 | 23,200 | -38,083 | 11,714 | 647 |
| 31 Mar 23 | 35,561 | -21,030 | 12,049 | 876 |
| 31 Dec 22 | 40,124 | -15,703 | 11,713 | 1,045 |
| 30 Sep 22 | 69,715 | -3,827 | 15,831 | 1,772 |
| 30 Jun 22 | 57,020 | -5,872 | 12,348 | 1,541 |
| 31 Mar 22 | 39,049 | -3,674 | 9,406 | 1,460 |
| 31 Dec 21 | 29,326 | -2,445 | 7,021 | 1,465 |
| 30 Sep 21 | 29,114 | 1,726 | 5,747 | 1,630 |
| 30 Jun 21 | 29,303 | 3,113 | 5,026 | 1,684 |
| 31 Mar 21 | 29,095 | 747 | 4,919 | 1,659 |
| 31 Dec 20 | 29,929 | -1,279 | 4,461 | 1,573 |
| 30 Sep 20 | 32,201 | -2,403 | 4,401 | 1,603 |
| 30 Jun 20 | 34,818 | -6,091 | 4,669 | 1,601 |
| 31 Mar 20 | 36,158 | -3,732 | 4,536 | 1,626 |
| 31 Dec 19 | 36,947 | -1,000 | 4,565 | 1,648 |
| 30 Sep 19 | 35,406 | -698 | 5,005 | 1,561 |
| 30 Jun 19 | 32,768 | 2,121 | 4,653 | 1,492 |
| 31 Mar 19 | 32,625 | 999 | 4,637 | 1,452 |
| 31 Dec 18 | 33,438 | -2,242 | 4,740 | 1,510 |
| 30 Sep 18 | 33,040 | -7,412 | 6,717 | 1,595 |
| 30 Jun 18 | 40,156 | -8,879 | 7,420 | 1,912 |
| 31 Mar 18 | 42,459 | -10,644 | 7,914 | 2,173 |
| 31 Dec 17 | 43,605 | -9,348 | 8,326 | 2,261 |
| 30 Sep 17 | 49,056 | -6,482 | 6,947 | 2,243 |
| 30 Jun 17 | 46,010 | -6,123 | 6,594 | 1,972 |
| 31 Mar 17 | 44,217 | -9,292 | 6,452 | 1,975 |
| 31 Dec 16 | 46,181 | -8,650 | 6,343 | 1,940 |
| 30 Sep 16 | 45,734 | -8,341 | 6,491 | 2,177 |
| 30 Jun 16 | 46,269 | -9,238 | 6,663 | 2,622 |
| 31 Mar 16 | 48,589 | -6,136 | 6,886 | 3,056 |
| 31 Dec 15 | 51,241 | -6,669 | 7,237 | 3,550 |
| 30 Sep 15 | 56,239 | -8,979 | 8,340 | 4,018 |
| 30 Jun 15 | 60,784 | -13,498 | 9,296 | 4,572 |
| 31 Mar 15 | 71,549 | -14,031 | 9,882 | 4,806 |
| 31 Dec 14 | 77,093 | -12,422 | 10,318 | 4,887 |
| 30 Sep 14 | 79,296 | -5,176 | 9,694 | 4,266 |
| 30 Jun 14 | 78,718 | 875 | 8,726 | 3,370 |
| 31 Mar 14 | 74,941 | 4,467 | 8,048 | 2,648 |
| 31 Dec 13 | 72,119 | 4,545 | 7,039 | 1,995 |
Quality Earnings: A060230 is currently unprofitable.
Growing Profit Margin: A060230 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A060230 is unprofitable, and losses have increased over the past 5 years at a rate of 67.5% per year.
Accelerating Growth: Unable to compare A060230's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A060230 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-5.1%).
Return on Equity
High ROE: A060230 has a negative Return on Equity (-32.75%), as it is currently unprofitable.